35 results on '"Bayne, Mike"'
Search Results
2. Infinite-order diagrammatic summation approach to explicitly correlated congruent transformed Hamiltonian
3. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
4. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
5. The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: Results of a prospective study with mature survival data
6. ctDNA analysis identifies clinically meaningful resistance mutations in EGFR mutated NSCLC on osimertinib: a case report
7. Nephrotoxicity in first-line systemic therapy for non-small cell lung cancer
8. An update on health-related quality of life from the PROCLIPI study
9. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
10. Interesting case of immunotherapy related pneumonitis presenting as radiation pneumonitis
11. Prevalence, treatment and outcomes of patients with advanced, non-squamous NSCLC (nsNSCLC) harbouring ALK or ROS1 gene-rearrangements in Dorset
12. Modern chemoradiation for lung cancer in Dorset. Real world experience with adjuvant durvalumab
13. Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung)
14. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
15. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
16. 161 - ctDNA analysis identifies clinically meaningful resistance mutations in EGFR mutated NSCLC on osimertinib: a case report
17. 76 - Nephrotoxicity in first-line systemic therapy for non-small cell lung cancer
18. Lesson learnt: severe skin reaction to somatostatin analogue injections
19. Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sezary syndrome and those with more extensive skin involvement
20. 186 - Interesting case of immunotherapy related pneumonitis presenting as radiation pneumonitis
21. Lymph node imaging in patch/plaque mycosis fungoides; enlarged LN are infrequent but lymphomatous nodal involvement may occur and upstage patients to advanced disease
22. Quality of life in patients with mycosis fungoides and Sezary syndrome is significantly worse in female patients, Sézary syndrome and those with more extensive skin involvement
23. Piloting a group programme aiming at psychologically supporting neuroendocrine patients
24. P2.05-055 90 Day Mortality and Survival Following Radical Radiotherapy for Non-Small Cell Lung Cancer Treated in the Dorset Cancer Centre, UK
25. Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria
26. Abstract C184: Validation of an ELISA for the determination of Rituximab pharmacokinetics in clinical trials subjects
27. Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin’s Lymphoma (NHL).
28. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
29. Apparent modulation of CD20 by rituximab: an alternative explanation
30. Antibody therapy of lymphoma
31. Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
32. Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria.
33. 89 - Prevalence, treatment and outcomes of patients with advanced, non-squamous NSCLC (nsNSCLC) harbouring ALK or ROS1 gene-rearrangements in Dorset.
34. 95 - Modern chemoradiation for lung cancer in Dorset. Real world experience with adjuvant durvalumab.
35. 34 - Changes in management for patients with lung cancer referred for radical radiotherapy during the first wave of the COVID 19 pandemic in the UK (COVID-RT Lung).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.